121 related articles for article (PubMed ID: 32291176)
1. Response to letter "resectable pancreas adenocarcinoma: the longer the wait time, the longer the oncologic survival?".
Vasilyeva E; Li J; Desai S; Scudamore C; Segedi M; Chung S; Kim P
HPB (Oxford); 2020 Jun; 22(6):934. PubMed ID: 32291176
[No Abstract] [Full Text] [Related]
2. Resectable pancreas adenocarcinoma: the longer the wait time, the longer the oncologic survival?
Chen ZL; Yang T; Liang YJ
HPB (Oxford); 2020 May; 22(5):789. PubMed ID: 32051091
[No Abstract] [Full Text] [Related]
3. Impact of surgical wait times on oncologic outcomes in resectable pancreas adenocarcinoma.
Vasilyeva E; Li J; Desai S; Chung SW; Scudamore CH; Segedi M; Kim PT
HPB (Oxford); 2020 Jun; 22(6):892-899. PubMed ID: 31732464
[TBL] [Abstract][Full Text] [Related]
4. Advances in borderline resectable pancreatic adenocarcinoma.
Vadehra D; Salibi PN; McHaffie DR; Sulzer J; Iannitti DA; Hwang JJ
Clin Adv Hematol Oncol; 2020 May; 18(5):280-288. PubMed ID: 32628656
[TBL] [Abstract][Full Text] [Related]
5. The effect of wait times on oncological outcomes from periampullary adenocarcinomas.
McLean SR; Karsanji D; Wilson J; Dixon E; Sutherland FR; Pasieka J; Ball C; Bathe OF
J Surg Oncol; 2013 Jun; 107(8):853-8. PubMed ID: 23625192
[TBL] [Abstract][Full Text] [Related]
6. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
Sa Cunha A; Rault A; Laurent C; Adhoute X; Vendrely V; Béllannée G; Brunet R; Collet D; Masson B
J Am Coll Surg; 2005 Sep; 201(3):359-65. PubMed ID: 16125068
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
9. Management of borderline resectable pancreatic adenocarcinoma.
Jia Y; Wang TJ; Allendorf J; Saif MW
JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy.
Sperti C; Pasquali C; Pastorelli D; Ferronato A; Decet G; Pedrazzoli S
Acta Biomed; 2003; 74 Suppl 2():91-5. PubMed ID: 15055044
[TBL] [Abstract][Full Text] [Related]
11. Aggressive therapy for cancer of the pancreas. Does it help?
Merrick HW; Dobelbower RR
Gastroenterol Clin North Am; 1990 Dec; 19(4):935-62. PubMed ID: 1702757
[TBL] [Abstract][Full Text] [Related]
12. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?
Marchegiani G; Andrianello S; Perri G; Secchettin E; Maggino L; Malleo G; Bassi C; Salvia R
HPB (Oxford); 2018 May; 20(5):411-417. PubMed ID: 29191689
[TBL] [Abstract][Full Text] [Related]
13. A ten-year study of carcinoma of the pancreas.
Atkins AR; Lindell TD; Fletcher WS
Am Surg; 1977 Oct; 43(10):660-5. PubMed ID: 71869
[TBL] [Abstract][Full Text] [Related]
14. Defining venous involvement in borderline resectable pancreatic cancer.
Chun YS; Milestone BN; Watson JC; Cohen SJ; Burtness B; Engstrom PF; Haluszka O; Tokar JL; Hall MJ; Denlinger CS; Astsaturov I; Hoffman JP
Ann Surg Oncol; 2010 Nov; 17(11):2832-8. PubMed ID: 20725860
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant therapy may allow unresectable tumors becoming resectable].
Sa Cunha A
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S113-6. PubMed ID: 26118869
[TBL] [Abstract][Full Text] [Related]
17. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas.
Evans DB; Hess KR; Pisters PW
Ann Surg; 2002 Nov; 236(5):694; author reply 694-6. PubMed ID: 12409677
[No Abstract] [Full Text] [Related]
18. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant strategies for resectable pancreatic cancer: have we made progress?
Russo S; Jain AK; Saif MW
JOP; 2012 Mar; 13(2):139-42. PubMed ID: 22406585
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al.
Adams RB; Allen PJ
Ann Surg Oncol; 2009 Jul; 16(7):1745-50. PubMed ID: 19396494
[No Abstract] [Full Text] [Related]
[Next] [New Search]
